(Q48860210)

16 February 2018

title

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. (English)

1 reference

16 February 2018

0 references

Dianna Rynkiewicz

1

1 reference

16 February 2018

Melinda Rathkopf

2

1 reference

16 February 2018

Iain Sim

3

1 reference

16 February 2018

A Thomas Waytes

4

1 reference

16 February 2018

Robert J Hopkins

5

1 reference

16 February 2018

Lallan Giri

6

1 reference

16 February 2018

Deborah DeMuria

7

1 reference

16 February 2018

Janet Ransom

8

1 reference

16 February 2018

James Quinn

9

1 reference

16 February 2018

Gary S Nabors

10

1 reference

16 February 2018

Carl J Nielsen

11

1 reference

16 February 2018

language of work or name

English

0 references

publication date

30 May 2011

1 reference

16 February 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

16 February 2018

volume

29

1 reference

16 February 2018

issue

37

1 reference

16 February 2018

page(s)

6313-6320

1 reference

16 February 2018

Anthrax vaccine: a review

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Search for correlates of protective immunity conferred by anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Systematic review: a century of inhalational anthrax cases from 1900 to 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Fatal inhalational anthrax in a 94-year-old Connecticut woman

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Observations on the prophylaxis of experimental pulmonary anthrax in the monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Postexposure prophylaxis against experimental inhalation anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Selection of Bacillus anthracis isolates resistant to antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Therapeutic potential of Toll-like receptor 9 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Adjuvant activity of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

CpG 7909: PF 3512676, PF-3512676

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Validation of the anthrax lethal toxin neutralization assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

In vitro correlate of immunity in a rabbit model of inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

A single-dose combination therapy that both prevents and treats anthrax infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

Effect of CpG oligonucleotides on vaccine-induced B cell memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.047

10.1016/J.VACCINE.2011.05.047

7 January 2021

Identifiers

DOI

1 reference

16 February 2018

PubMed ID

21624418

1 reference

16 February 2018